Summary

Sequential or concurrent treatment with the vaccine GV100 with chemotherapy does not result in a survival advantage in patients with advanced pancreatic cancer. This article discusses data from the fourth interim analysis of the Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer study [TeloVac; NCT00425360; Middleton GW et al. J Clin Oncol 2013 (suppl; abstr LBA4004)].